Search
Rezafungin
go.drugbank.com/drugs/DB16310ApprovedInvestigationalRezafungin has a half-life higher than 130 hours and can be administered once a week instead of daily. ā¦ [A258393,L45633] Unlike other echinocandins such as [caspofungin] and [micafungin], rezafungin has longāacting pharmacokinetics and a high stability that allows for it to have long dosing intervals maintaining
Categories: Heterocyclic Compounds, 1-RingSynonyms: Echinocandin B, 1-((4R,5R)-4-hydroxy-N2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-5-(2-(trimethylammonio)ethoxy)-l-ornithine)-4-((4S)-4-hydroxy-4-(4-hydroxyphenyl)-l-allothreonine)-Sepiapterin
go.drugbank.com/drugs/DB16326ApprovedInvestigationalSepiapterin is a small molecule activator of phenylalanine hydroxylase (PAH) used to reduce phenyalanine levels in patients with phenylketonuria. ā¦ It is a natural precursor of the enzymatic co-factor tetrahydrobiopterin (BH4), which activates PAH and helps reduce blood phenylalanine levels by enhancing the conformational stability of misfolded PAH
Categories: Heterocyclic Compounds, 2-RingSynonyms: L-sepiapterinMobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawnMobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). ā¦ It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis (
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsFosdenopterin
go.drugbank.com/drugs/DB16628ApprovedIn 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A. ā¦ [A230088] Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity.
Categories: MATE 1 Substrates, MATE 2 InhibitorsSynonyms: C(PMP)Serdexmethylphenidate
go.drugbank.com/drugs/DB16629Approved[L32298, L32323] Serdexmethylphenidate was granted FDA approval on March 2, 2021, and is currently marketed as a combination capsule with [dexmethylphenidate] under the trademark AZSTARYSā¢ by KemPharm ā¦ [A230698, A230708] Serdexmethylphenidate is a prodrug of the CNS stimulant [dexmethylphenidate], a common first-line treatment for ADHD, that is combined with [dexmethylphenidate] to provide extended plasma
KW-2450 free base
go.drugbank.com/drugs/DB16637InvestigationalCategories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingReltecimod
go.drugbank.com/drugs/DB16687InvestigationalReltecimod is under investigation in clinical trial NCT02469857 (Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections).
Synonyms: D-alanyl-L-seryl-L-prolyl-L-methionyl-L-leucyl-L-valyl-L-alanyl-L-tyrosyl-L-aspartyl-D-alanineCategories: Antigens, Differentiation, T-Lymphocyte, Costimulatory and Inhibitory T-Cell ReceptorsNirmatrelvir
go.drugbank.com/drugs/DB16691ApprovedInvestigational[L33354] 3CL<sup>PRO</sup> is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2. ā¦ [A234224,A234229,A234234] In 2020, Pfizer was investigating another potential treatment for SARS-CoV-2, [PF-07304814].
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesDurlobactam
go.drugbank.com/drugs/DB16704ApprovedInvestigationalDurlobactam is a diazabicyclooctane non-beta-lactam, beta-lactamase inhibitor. It is typically given in combination with [sulbactam] to protect it from degradation by certain serine-beta-lactamases.
Synonyms: (2S,5R)-2-CARBAMOYL-3-METHYL-7-OXO-1,6-DIAZABICYCLO(3.2.1)OCT-3-EN-6-YL SULFATE, SULFURIC ACID, MONO((2S,5R)-2-(AMINOCARBONYL)-3-METHYL-7-OXO-1,6-DIAZABICYCLO(3.2.1)OCT-3-EN-6-YL) ESTERAzasetron
go.drugbank.com/drugs/DB16837InvestigationalCategories: P-glycoprotein substrates, Heterocyclic Compounds, 1-Ring